Pembrolizumab biosimilar - R-Pharm
Alternative Names: RPH 075Latest Information Update: 27 Mar 2024
At a glance
- Originator R-Pharm
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma
- Phase I Non-small cell lung cancer; Squamous cell cancer